Magnus Financial Group’s Novartis NVS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$436K Hold
2,782
0.03% 260
2026
Q1
$425K Sell
2,782
-35
-1% -$5.37K 0.03% 245
2025
Q4
$388K Hold
2,817
0.03% 298
2025
Q3
$361K Buy
2,817
+29
+1% +$3.54K 0.03% 294
2025
Q2
$337K Buy
2,788
+139
+5% +$15.7K 0.03% 285
2025
Q1
$295K Buy
2,649
+4
+0.2% +$426 0.03% 283
2024
Q4
$257K Hold
2,645
0.02% 301
2024
Q3
$304K Hold
2,645
0.03% 270
2024
Q2
$282K Buy
2,645
+25
+1% +$2.51K 0.03% 262
2024
Q1
$253K Sell
2,620
-27
-1% -$2.77K 0.03% 275
2023
Q4
$267K Buy
2,647
+27
+1% +$2.61K 0.04% 240
2023
Q3
$267K Hold
2,620
0.04% 220
2023
Q2
$264K Hold
2,620
0.04% 227
2023
Q1
$241K Buy
2,620
+136
+5% +$11.9K 0.04% 242
2022
Q4
$225K Buy
+2,484
New +$209K 0.04% 238
2022
Q3
Sell
-2,571
Closed -$217K 279
2022
Q2
$217K Buy
2,571
+100
+4% +$8.77K 0.04% 252
2022
Q1
$217K Buy
2,471
+15
+0.6% +$1.3K 0.04% 263
2021
Q4
$215K Hold
2,456
0.04% 236
2021
Q3
$201K Hold
2,456
0.04% 234
2021
Q2
$224K Hold
2,456
0.05% 219
2021
Q1
$210K Sell
2,456
-22
-0.9% -$1.97K 0.05% 215
2020
Q4
$234K Buy
2,478
+58
+2% +$5.07K 0.02% 262
2020
Q3
$210K Buy
+2,420
New +$210K 0.02% 259

Other funds holding NVS

Magnus Financial Group's NVS Position: Q2 2026 in Review

Magnus Financial Group held its Novartis (NVS) position steady in Q2 2026 at 2,782 shares worth $436K. The position accounts for 0.03% of the portfolio, ranked #260.

Magnus Financial Group first reported a position in NVS in Q3 2020 and has held it in 23 quarters since. 509 funds tracked by Wall St. Rank hold NVS as of Q2 2026.

  • Magnus Financial Group held 2,782 shares of Novartis worth $436K as of Q2 2026.
  • Magnus Financial Group left its Novartis share count unchanged in Q2 2026.
  • Novartis made up 0.03% of Magnus Financial Group's portfolio in Q2 2026, its #260 holding.
  • Magnus Financial Group first reported a position in Novartis in Q3 2020 and has held it in 23 quarters since.
  • 509 funds tracked by Wall St. Rank held Novartis as of Q2 2026.

Based on Magnus Financial Group's 13F filing for Q2 2026, filed 9 Jul 2026.